HYBRID EVENT: You can participate in person at Paris, France or Virtually from your home or work.

2nd Edition of International Heart Congress

June 20-22,2024 | Hybrid Event

June 20 -22, 2024 | Paris, France
Heart Congress 2024

Clinical pharmacology of sotagliflozin – Novel quality in treatment of heart failure

Miroslav Radenkovic, Speaker at Cardiology Conferences
University of Belgrade, Serbia
Title : Clinical pharmacology of sotagliflozin – Novel quality in treatment of heart failure


Heart failure is a serious clinical syndrome with symptoms and signs provoked by a structural and functional cardiac abnormality, and coupled with elevated natriuretic peptide levels and evident pulmonary or systemic congestion. Regardless of outstanding improvements in the management of heart failure over the past period, its prognosis is still poor with notable rates of mortality and hospitalization due to worsening of overall clinical presentation. Sodium-glucose cotransporter-2 (SGLT2) inhibitors are relatively novel glucose-lowering drugs that furthermore promote weight loss and the reduction of blood pressure. Moreover, the data from ground-breaking trials clearly demonstrated that the beneficial effects of SGLT2 inhibitors extended to non-diabetic patients with chronic kidney disease and/or heart failure with reduced ejection fraction. Still, the risks vs. benefits in each patient should be carefully analyzed and weighed when making a prescribing decision due to known adverse drug reactions to SGLT2 inhibitors. Sotagliflozin is a recently registered SGLT2 inhibitor prescribed to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors. Given the previous facts, the main objectives of this presentation will be to clarify the pharmacological features of sotagliflozin, including pharmacodynamics, pharmacokinetics, indications, and contraindications for use, adverse drug reactions, as well as the most important drug interactions. This will provide a better understanding of this new-in-pharmacotherapy drug for heart failure, consequently helping clinicians in its suitable prescribing and adequate clinical use.


Miroslav Radenković, MD, MS, PhD, a full-time professor at the Department of Pharmacology, Clinical Pharmacology and Toxicology, graduated from the Faculty of Medicine – University of Belgrade (FMUB) in 1995, and from 1996 he is working at the FMUB. He received an MS from pharmacology, board certified in Clinical Pharmacology, PhD from Medical Sciences, and a sub-specialization degree in Clinical Pharmacology - Pharmacotherapy in 1999, 2000, 2004, and 2016 respectively, from the FMUB, as well as Bioethics MS in 2021 from the Clarkson University, NYC, USA. From 2002 Dr. Radenković officially participated in several scientific projects supported by the Ministry of Science – Serbia; the Austrian Science Fund; COST Action; as well as the NIH Fogarty International Center Project, USA. Dr. Radenković is a member of the Ethics Committee of Serbia.